item management s discussion and analysis of financial condition and results of operations the following discussion includes certain forward looking statements 
such forward looking statements are subject to a number of factors  including material risks  uncertainties and contingencies  which could cause actual results to differ materially from the forward looking statements 
for a discussion of important factors that could cause actual results to differ materially from the forward looking statements  see exhibit to this report and the company s periodic reports and other documents filed with the commission 
results of operations the following table presents for the three years ended august  statements of income expressed as a percentage of net sales and the period to period changes in the dollar amounts of the respective line items 
period to period percentage of net sales percentage increase year ended august  vs vs vs net sales gross profit operating expenses research  development and engineering selling  general and administrative operating income other expenses income  net income before income taxes provision for income taxes net income not a meaningful comparison fiscal compared to fiscal net sales increased by million  or  to million in fiscal from million in fiscal net sales represent gross sales invoiced to customers  plus royalty income  less certain related charges  including freight costs  discounts  returns and other allowances 
this increase was due primarily to an increase in unit shipments of central venous catheters  including increased shipments of arrowg ard tm blue r antiseptic surface treated catheter products  pain management catheters  and implantable constant flow drug delivery pumps 
sales of critical care products increased to million from million in fiscal sales of cardiac care products decreased to million from million in the previous year  due primarily to decreased shipments of intra aortic balloon pump and catheter products in japan  where the company is transitioning from a dealer to direct sales 
international sales increased by million  and represented of net sales  excluding royalty income  in fiscal  compared to in the prior year  principally as a result of growth in shipments of multi lumen catheters  offset by the effect of the stronger us dollar on sales in significant foreign markets and by reduced shipments of intra aortic balloon pump and catheter products in japan 
the percentage of net sales attributable to the company s direct sales force decreased in fiscal to approximately from approximately in fiscal  principally as a result of the effect of the stronger us dollar on sales in significant foreign markets where the company has direct sales subsidiaries 
this increase in net sales was lower than the company anticipated due to decreased shipments of intra aortic balloon products  the strength of the us dollar in significant foreign markets and slower than expected new product introductions 
health care cost containment initiatives in the us have reduced growth in demand in markets where arrow has or greater market shares  and protecting that market share has affected the company s pricing in some instances 
the company anticipates increased us sales of several products in fiscal  however  us demand for certain of the company s core products is expected to remain sluggish 
the company also anticipates that fiscal international sales will grow more rapidly than us sales due to rising demand in several regions of the world  supported by increased production in the company s mexico and czech republic manufacturing facilities and the completion of the transition from dealer to direct sales of intra aortic balloon products in japan 
continued strengthening of the us dollar  however  would adversely affect this expectation 
a return to the company s traditionally higher rates of sales growth is dependent on demand for its new products now in various stages of market introduction  as well as timely receipt of required regulatory approvals and timely completion of research and development programs 
gross profit increased to million in fiscal from million in fiscal as a percentage of net sales  gross profit improved to in fiscal from in the prior year  due primarily to the reduction in manufacturing costs resulting from increased production at the company s manufacturing facilities in mexico and the czech republic and increased sales of higher margin arrowg ard tm blue r antiseptic surface treated catheter products  offset by the unfavorable impact of currency translations of foreign sales 
research  development and engineering expenses in fiscal increased by to million from million in fiscal as a percentage of net sales  these expenses increased to in fiscal  compared to in fiscal these expenses increased primarily as a result of development expenses related to several new products  including the company s left ventricular assist device lvad 
selling  general and administrative expenses increased by to million during fiscal from million in the previous year  and decreased as a percentage of net sales to in fiscal  compared to in fiscal this percentage decrease was due primarily to successful efforts to restrain the growth in these expenditures in view of the prior year s expansion of the company s us salesforces and japanese and european direct sales subsidiaries 
fiscal compared to fiscal continued principally due to the above factors  operating income increased to million in fiscal from million in fiscal other expenses income  net  decreased to million in fiscal from million in fiscal  due to a reduction in interest expense  offset by increased losses due to foreign exchange translation 
other expenses income  net  consists principally of interest expense and foreign exchange gains and losses associated with the company s direct sales subsidiaries 
aggregate foreign exchange gains and losses in fiscal and were million and million  respectively  including gains and losses relating to foreign currency contracts of and million  respectively 
as a result of the factors discussed above  income before income taxes increased in fiscal by to million from million in fiscal the effective income tax rate increased to in fiscal from in fiscal  principally as a result of the provision for taxes in certain state and international jurisdictions 
net income in fiscal increased by to million from million in fiscal as a percentage of net sales  net income represented in fiscal compared to in the previous year 
net income per common share increased to for fiscal  an increase of  or  per share  from per share in fiscal weighted average common shares outstanding decreased to  in fiscal from  in fiscal as a result of the forfeiture of unvested restricted stock awards by certain former employees 
fiscal compared to fiscal net sales increased by million  or  to million in fiscal from million in fiscal this increase was due primarily to an increase in unit volume in the company s major product lines  including increased shipments of arrowg ard tm blue r antiseptic surface treated catheter products 
sales of critical care products increased to million from million in fiscal sales of cardiac care products increased to million from million in the previous year 
international sales increased by million  or  to of net sales  excluding royalty income  in fiscal  compared to in the prior year  principally as a result of growth in shipments of multi lumen catheters and intra aortic balloon catheters 
the percentage of net sales attributable to the company s direct sales force increased in fiscal to approximately from approximately in fiscal  principally as a result of the company s gradual conversion of dealer based sales to direct sales 
this increase in net sales was lower than the company anticipated due to an unforeseen reduction in the rate of growth in the us market for certain high volume products  the strength of the us dollar  particularly against the japanese yen  and slower than anticipated new product introductions 
health care cost containment initiatives in the us reduced growth in demand in markets where arrow has or greater market shares  and protecting that market share affected the company s pricing in some instances 
gross profit increased to million in fiscal from million in fiscal as a percentage of net sales  gross profit improved to in fiscal from in the prior year  due primarily to the reduction in manufacturing costs resulting from the company s new sterilization facility which does not require the use of freon gas  operating efficiencies created by increased production at the company s manufacturing facility in mexico and increased sales of higher margin arrowg ard tm blue r antiseptic surface treated catheter fiscal compared to fiscal continued products 
this increase was lower than the company anticipated due principally to the unfavorable impact of currency translations of foreign sales 
research  development and engineering expenses in fiscal increased by to million from million in fiscal as a percentage of net sales  these expenses increased to in fiscal  compared to in fiscal these expenses increased primarily as a result of development expenses related to certain products of therex  which was acquired in april  and certain cardiac assist products 
selling  general and administrative expenses increased by to million during fiscal from million in the previous year  and increased as a percentage of net sales to in fiscal  compared to in fiscal this percentage increase was due primarily to additions to the domestic direct sales force to replace a distributor in the new england area  the expansion of the company s japanese and european sales subsidiaries and the addition of expenses related to therex 
principally due to the above factors  operating income increased to million in fiscal from million in fiscal other expenses income  net  increased to million in fiscal from million in fiscal other expenses income  net  consists principally of interest expense and foreign exchange gains and losses associated with the company s direct sales subsidiaries 
aggregate foreign exchange gains and losses in fiscal and were million and million  including gains and losses relating to foreign currency contracts of and million  respectively 
as a result of the factors discussed above  income before income taxes decreased in fiscal by to million from million in fiscal the effective income tax rate increased to in fiscal from in fiscal  principally as a result of generating a larger proportion of earnings in higher tax jurisdictions and the reduction in the benefit of the research and development tax credit prior to its reinstatement on july  net income in fiscal decreased by to million from million in fiscal as a percentage of net sales  net income represented in fiscal compared to in the previous year 
net income per common share decreased to for fiscal  a decrease of  or per share  from per share in fiscal weighted average common shares outstanding increased to  in fiscal from  in fiscal as a result of the issuance on april  of  shares of common stock in connection with the acquisition of therex and the issuance on may  of  shares of common stock in an underwritten public offering by the company 
liquidity and capital resources for the year ended august   net cash provided by operations was million  an increase of million from the prior year 
this increase was due primarily to an increase in net income 
accounts receivable increased by million for the year ended august   compared to a million increase in the prior year 
accounts receivable  measured in days sales outstanding  increased to days at august   from days at august   due principally to an increase in the collection period for both us and international sales 
liquidity and capital resources continued net cash used in the company s investing activities decreased to million in fiscal from million in the prior year  principally as a result of the completion in fiscal of the construction and equipping of the company s new manufacturing and research facility in the czech republic 
net cash used in financing activities increased to million in fiscal  compared to providing million in fiscal this change resulted principally from a decrease in short term borrowings and repayment of long term debt 
as of august   the company had us bank credit facilities providing a total of million in available revolving credit for general business purposes  of which million remained unused 
in addition  certain of the company s foreign subsidiaries have revolving credit facilities totaling the us dollar equivalent of million  of which million remained unused as of august  combined borrowing under these credit facilities decreased million and increased million during the years ended august  and  respectively 
during fiscal  and  the percentage of the company s sales invoiced in currencies other than the us dollar was  and  respectively 
in addition  a small part of the company s cost of goods sold is denominated in foreign currencies 
as a partial hedge against adverse fluctuations in exchange rates  the company periodically enters into foreign currency exchange contracts with certain major financial institutions 
by their nature  all such contracts involve risk  including the risk of nonperformance by counterparties 
accordingly  losses relating to these contracts could have a material adverse effect upon the company s business  financial condition and results of operations 
based upon the company s knowledge of the financial condition of the counterparties to its existing forward contracts  the company believes that it does not have any material exposure to any individual counterparty 
the company s policy prohibits the use of derivative instruments for speculative purposes 
as of november   outstanding foreign currency exchange contracts totaling the us dollar equivalent of million mature at various dates through august the company expects to continue to utilize foreign currency exchange contracts to manage its exposure  although there can be no assurance that the company s efforts in this regard will be successful 
based upon its present plans  the company believes that its working capital  operating cash flow and available credit sources will be adequate to repay current portions of long term debt  to finance currently planned capital expenditures and to meet the currently foreseeable liquidity needs of the company 
during the periods discussed above  the overall effects of inflation and seasonality on the company s business were not significant 
statements of financial accounting standards not yet adopted in february  the financial accounting standards board fasb issued statement of financial accounting standards no 
 earnings per share fas 
fas is designed to improve the earnings per share eps information provided in financial statements by simplifying the existing computational guidelines  revising the disclosure requirements and increasing the comparability of eps data on an international basis 
the statement is effective for financial statements for periods ending after december   with prior periods restated to comply with the new standard at that time 
if the new standard had been effective for the year ended august   there would have been no significant change in earnings per share as presented in the accompanying consolidated statements of income 
continued liquidity and capital resources continued in february  the financial accounting standards board fasb issued statement of financial accounting standards no 
 disclosure of information about capital structure fas 
fas establishes standards for disclosing information about an entity s capital structure 
the statement is effective for financial statements for periods ending after december  the company does not anticipate the adoption of this new standard to have a material effect on the company s consolidated financial statements 
in june  the financial accounting standards board fasb issued statement of financial accounting standards no 
 reporting comprehensive income fas 
fas establishes standards for reporting and display of comprehensive income and its components in a full set of general purpose financial statements 
the statement is effective for financial statements for fiscal years beginning after december  the company does not anticipate the adoption of this new standard to have a material effect on the company s consolidated financial statements 
in june  the financial accounting standard board fasb issued statement of financial accounting standards no 
 disclosures about segments of an enterprise and related information fas 
fas establishes revised guidelines for determining an entity s operating segments and the type and level of financial information to be disclosed 
fas requires entity wide disclosure of information about revenues from different products and services and geographic areas 
the statement is effective for financial statements for fiscal years beginning after december  the company does not anticipate the adoption of this new standard to have a material effect on the company s consolidated financial statements 
item a 
quantitative and qualitative disclosures about market risk not applicable to the company prior to its annual report on form k for the fiscal year ended august  
